In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
These combination products are generally promoted for their antioxidant, anti-inflammatory, or neuroprotective properties, rather than for gynecological or endocrine-related indications
In children and young adults, the total antioxidant capacity (TAC) and catalase levels were reduced in different types of malnutrition and recovered after dietary intake improvement and weight recovery (16)
Its estimated that 40% of the general population have one of the two variants
An enzymatic assay was also performed to quantify total and oxidized glutathione levels from homogenized tissue
(PubMed) Ziegler D, Ametov A, Barinov A, et al